DK421687A - Vector virus carrying a heterologous DNA sequence - Google Patents

Vector virus carrying a heterologous DNA sequence

Info

Publication number
DK421687A
DK421687A DK421687A DK421687A DK421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A
Authority
DK
Denmark
Prior art keywords
dna sequence
heterologous dna
virus carrying
vector virus
tumour
Prior art date
Application number
DK421687A
Other languages
Danish (da)
Other versions
DK173755B1 (en
DK421687D0 (en
Inventor
Richard Lathe
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of DK421687D0 publication Critical patent/DK421687D0/en
Publication of DK421687A publication Critical patent/DK421687A/en
Application granted granted Critical
Publication of DK173755B1 publication Critical patent/DK173755B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A recombinant virus characterised in that it contains all or part of the sequence of a specific antigen of a tumour and in that it is employed by way of prevention or cure, to cause the rejection of the corresponding tumour in man or in animals.
DK198704216A 1986-08-13 1987-08-12 Pharmaceutical composition comprising a viral vector DK173755B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8611700A FR2602790B1 (en) 1986-08-13 1986-08-13 EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR
FR8611700 1986-08-13

Publications (3)

Publication Number Publication Date
DK421687D0 DK421687D0 (en) 1987-08-12
DK421687A true DK421687A (en) 1988-02-14
DK173755B1 DK173755B1 (en) 2001-09-10

Family

ID=9338277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198704216A DK173755B1 (en) 1986-08-13 1987-08-12 Pharmaceutical composition comprising a viral vector

Country Status (9)

Country Link
EP (1) EP0259212B1 (en)
JP (2) JP2852515B2 (en)
AT (1) ATE101648T1 (en)
AU (1) AU619448B2 (en)
CA (1) CA1341241C (en)
DE (1) DE3789082T2 (en)
DK (1) DK173755B1 (en)
ES (1) ES2061520T3 (en)
FR (1) FR2602790B1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222165B (en) * 1988-08-20 1992-06-17 Animal Health Inst Recombinant capripoxvirus
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
DE69826124T3 (en) 1997-06-30 2007-10-11 Institut Gustave Roussy ADMINISTRATION OF NUCLEIC ACID IN CROSS-LINKED MUSCLES
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
FR2799472B1 (en) 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
PT1301213T (en) 2000-07-21 2017-04-19 Revance Therapeutics Inc Multi-component biological transport systems
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
FR2829136B1 (en) 2001-08-29 2006-11-17 Aventis Pharma Sa LIPID DERIVATIVES OF AMINOGLYCOSIDES
PT1479985T (en) 2002-01-17 2017-08-03 Alfa Laval Corp Ab Submerged evaporator comprising a plate heat exchanger and a cylindric casing where the plate heat exchanger is arranged
ES2335657T3 (en) 2002-04-25 2010-03-31 Crucell Holland B.V. MEANS AND METHODS FOR THE PRODUCTION OF ADENOVIRUS VECTORS.
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
KR20110116016A (en) * 2009-01-20 2011-10-24 트랜스진 에스.에이. Soluble icam-1 as biomarker for prediction of therapeutic response
WO2016075314A1 (en) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification of yarrowia lipolytica transcription factors that affect protein production
FR3028527A1 (en) 2014-11-13 2016-05-20 Pivert IDENTIFICATION OF TRANSCRIPTION FACTORS OF YARROWIA LIPOLYTICA
FR3081169B1 (en) 2018-05-15 2020-06-19 Messenger Biopharma SUBSTITUTION OF THE HAT OF MESSENGER RNAS BY TWO RNA SEQUENCES INTRODUCED AT THEIR 5 'END

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
AU623333B2 (en) * 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same

Also Published As

Publication number Publication date
DK173755B1 (en) 2001-09-10
JP2852515B2 (en) 1999-02-03
DE3789082T2 (en) 1994-09-01
AU7679787A (en) 1988-02-18
FR2602790A1 (en) 1988-02-19
FR2602790B1 (en) 1990-06-01
EP0259212A1 (en) 1988-03-09
ATE101648T1 (en) 1994-03-15
DE3789082D1 (en) 1994-03-24
ES2061520T3 (en) 1994-12-16
JPS6349077A (en) 1988-03-01
AU619448B2 (en) 1992-01-30
CA1341241C (en) 2001-06-05
JPH09173061A (en) 1997-07-08
DK421687D0 (en) 1987-08-12
EP0259212B1 (en) 1994-02-16

Similar Documents

Publication Publication Date Title
DK421687D0 (en) Vector virus carrying a heterologous DNA sequence
ATE112802T1 (en) PRODUCTION OF FUNCTIONAL HUMAN UROKINASEPOLYPEPTIDES.
ATE91714T1 (en) TRANSFORMATION OF TRICHODERMA.
DK143492A (en) HUMAN-H2-PRAEPRORELAXIN, -PRORELAXIN AND -RELAXIN, AND POLYPEPTIDE WITH RELAXIN ACTIVITY
DE10399037I2 (en) Recombinant virus proteins accompanied by lymphadenopathic sydrome and / or "Acquired Immune Deficiency Syndrome" (AIDS).
DE3675649D1 (en) ASSEMBLY OF SYRINGE CONTAINERS.
KR860005020A (en) Method for producing horse and dog interferon
ATE162079T1 (en) USE OF PREPARATIONS CONTAINING ANTIBODIES FOR IMMUNOSUPRESSION
FI852683A0 (en) IMMUNE MOTHER FOLLOWING TUMOERER AND VIRUS.
DK366483A (en) GENES, DNA TRANSFER VECTOR OR SUBSTANCE THAT CODES FOR HUMAN PREPRORELAXIN OR A SUBSTANCE THEREFORE
FI99116B (en) Process for producing horse interferon
DK606285D0 (en) VACCINE v. RABIES AND PROCEDURE FOR PREPARING THEREOF
ATE108333T1 (en) PRODUCTION AND USE OF ANTI-HELMINTHIC AGENTS AND PROTECTIVE ANTIGENS.
FI853389A0 (en) TUMOERLAEKEMEDEL OCH FOERFARANDE FOER DESS FRAMSTAELLNING.
ATE136933T1 (en) RECOMBINANT HBSAG HYBRID PARTICLES HAVING MORPHOLOGICAL CHARACTERISTICS OF HBSAG ANTIGEN AND CONTAINING AN IMMUNOGENIC SEQUENCE THAT INDUCES NEUTRALIZING ANTIBODIES AGAINST HIV OR THAT IS RECOGNIZED BY THESE ANTIBODIES, NUCLEOTIDE SEQUENCES ENCODING THESE PARTICLES AND VACCINE CONTAINING THEM E
DE59310073D1 (en) Method for inactivating viruses in protein preparations
DK513687A (en) MONOCLONAL ANTIBODIES FOR IFN-OMEGA, THEIR PROCEDURES FOR THEIR PREPARATION AND THEIR USE OF PURIFICATION AND THE DETECTION OF IFN-OMEGA
SU994372A1 (en) Conveyer loading/unloading mechanism
AT388848B (en) PREPARATIONS FOR IMPROVING THE WEIGHT GAIN AND THE FORAGE USE BY ANIMALS
NO871737D0 (en) RECOMBINANT VIRUS, POLYPEPTIDE AND DNA MOLECULE WITH THE CODING SEQUENCE OF THIS POLYPEPTIDE.
ATE52798T1 (en) RECOMBINANT PLASMID CONTAINING HEPATITIS B VIRUS GENE, YEAST TRANSFORMED WITH SUCH RECOMBINANT PLASMID AND PRODUCTION OF HEPATITIS B VIRUS SURFACE ANTIGEN.
ATE23798T1 (en) VIRUSES WITH RECOMBINANT SURFACE PROTEINS.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK